Long-term natalizumab treatment is associated with sustained improvements in quality of life in patients with multiple sclerosis
| Autor: | Timothy Vollmer, Judith J. Stephenson, Sonalee Agarwal, John F. Foley, Crystal Watson, Kavita V. Nair, Timothy Niecko |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Physical disability Population Medicine (miscellaneous) 03 medical and health sciences 0302 clinical medicine Natalizumab natalizumab Quality of life Internal medicine medicine In patient education Pharmacology Toxicology and Pharmaceutics (miscellaneous) Original Research education.field_of_study business.industry Health Policy Multiple sclerosis relapsing multiple sclerosis medicine.disease Clinical trial health-related quality of life long-term efficacy 030104 developmental biology Patient Preference and Adherence patientreported outcome Observational study business 030217 neurology & neurosurgery Social Sciences (miscellaneous) medicine.drug |
| Zdroj: | Patient preference and adherence |
| ISSN: | 1177-889X |
| Popis: | John F Foley,1 Kavita V Nair,2 Timothy Vollmer,3 Judith J Stephenson,4 Timothy Niecko,5 Sonalee S Agarwal,6 Crystal Watson6 1Rocky Mountain Multiple Sclerosis Clinic, Salt Lake City, UT, USA; 2Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Denver, Aurora, CO, USA; 3Department of Neurology, University of Colorado School of Medicine, Aurora, CO, USA; 4HealthCore, Inc., Wilmington, DE, USA; 5Niecko Health Economics, Tierra Verde, FL, USA; 6Biogen, Cambridge, MA, USA Background: Multiple sclerosis (MS) patients experience lower health-related quality of life (HRQoL) than the general population. In clinical trials, natalizumab significantly improved HRQoL and reduced relapse rates and disability progression in patients with relapsing MS. In a 1-year analysis of patients included in the current study, HRQoL improvement occurred within 3 months of natalizumab initiation and continued for 1 year thereafter. However, natalizumab’s long-term efficacy in improving HRQoL has not been studied.Methods: In this longitudinal, observational, single-arm US study, HRQoL and treatment satisfaction were evaluated in MS patients receiving intravenous natalizumab 300mg every 4 weeks in clinical settings. Patients completed surveys at baseline and every 6 months for 3 years and reported the following measures: Short Form-12 Version 2 (SF-12v2), Multiple Sclerosis Impact Scale (MSIS-29), and Treatment Satisfaction Questionnaire for Medication.Results: In this study, 120 patients completed ≥3 years of natalizumab treatment. Significant HRQoL improvements were evident from baseline to year 3 by increases in SF-12v2 Physical Component Summary (PCS) and Mental Component Summary scores (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|